Abstract MicroRNA-122 (miR-122), a highly abundant and liver-specific miRNA, acts as a tumor suppressor against hepatocellular carcinoma (HCC). Decreased expression of miR-122 in HCC is frequently observed and is associated with poor differentiation, larger tumor size, metastasis and invasion, and poor prognosis. Mutant mice with knockout
Introduction
MicroRNA122 (miR-122) accounts for 70 % of the total liver miRNA population, but it is undetectable in other tissues [1] [2] [3] . MiR-122 plays important roles in regulating hepatocyte development, differentiation, lipid metabolism, and stress response [2] [3] [4] [5] . With regard to liver diseases, miR-122 stimulates hepatitis C virus (HCV) replication by direct binding to HCV 5 0 UTR of HCV RNA [4, 6, 7] , whereas miR-122 inhibits replication of hepatitis B virus (HBV) by p53-mediated inhibition of HBV transcription [7, 8] . MiR-122 acts as a tumor suppressor and represses hepatocellular carcinoma (HCC) development by binding to target genes involved in cell proliferation, migration, differentiation, apoptosis and angiogenesis in HCC [3, 5] . In this review, we focus on the antitumor activity of miR-122 against HCC and describe miR-122 expression in HCC, hepatocarcinogenesis in miR-122 knockout mice, mechanisms of antitumor function of miR-122, regulation of miR-122 gene expression, and therapeutic application of miR-122 against HCC. [9] [10] [11] [12] [13] [14] [15] . Loss of miR-122 expression in HCC is associated with metastasis and poor prognosis [10, [12] [13] [14] [15] . Coulouarn et al. reported that the overall survival of patients with low and high miR-122 expression in HCC was 30.3 ± 8.0 and 83.7 ± 10.3 months, respectively (p \ 0.001), and that miR-122 repression was associated with poor differentiation status and large tumor size. They also found that the loss of miR-122 expression in HCC tissue was correlated with high proliferation and low apoptotic index [10] . Down-regulation of miR-122 is also observed in numerous human HCC cell lines, although the levels of miR-122 are variable with more than 1000-fold expression differences among cell lines [10] . Lower expression levels of miR-122 are related to the migration and invasion activity of HCC cells [11] .
Serum levels of miR-122 have been determined in patients with chronic liver disease including HCC [16] [17] [18] . The miR-122 levels did not significantly differ between patients with and without HCC, but were positively correlated with liver transaminases and negatively correlated with the Model for End-Stage Liver Disease (MELD) score [18] , suggesting that serum miR-122 is a novel biomarker for liver injury but not specifically for HCC.
Hepatocarcinogenesis in miR-122 knockout mice
To elucidate the relevance of miR-122 depletion and HCC development, mutant mice with germ line knockout (KO) or liver-specific knockout (LKO) of the miR-122 locus were generated in two studies [19, 20] , and the pathophysiological changes in these mutant mice were investigated. Both KO and LKO mice develop normally and are viable and indistinguishable from wild-type (WT) mice. Both mice exhibit reduced serum cholesterol and triglyceride (TG) levels and develop hepatic steatosis due to TG accumulation and reduced glycogen storage, as well as inflammation and fibrosis. These histological features are similar to steatohepatitis. Eventually, HCC developed in 10-month-old KO mice and 12-month-old LKO mice. The incidence of HCC exhibited significant sex differences; HCC developed in 17 of 19 (89 %) male KO mice and 6 of 26 (23 %) female KO mice [19] , and in 13 of 26 (50 %) male LKO mice and 2 of 20 (10 %) female LKO mice [20] .
In the miR-122 KO liver, the expression of Agpat1, which catalyzes TG biosynthesis [21] , was up-regulated, and the expression of Cidec (Fsp27), a lipid droplet-binding protein that promotes TG accumulation in hepatocytes [22] , was also elevated. 3 0 UTRs of both Agpat1 and Cidec mRNA contain miR-122 binding sites [20] . MiR-122 significantly repressed luciferase expression from reporter plasmids containing 3 0 UTRs of these genes [20] . In addition, the expression of microsomal TG transfer protein (MTTP), which plays a crucial role in hepatic very lowdensity lipoprotein (VLDL) assembly and secretion [23] , was reduced in both mRNA and protein levels. Hydrodynamic injection of the MTTP gene in miR-122 KO mice resulted in an increase in serum VLDL as well as in normalization of serum levels of cholesterol and TG. Surprisingly, the MTTP-restored liver showed significant reduction of hepatic steatosis, inflammation, and fibrosis, as well as recovery of glycogen storage [19] . These results suggest that TG accumulation in the miR-122 KO liver is caused by an increase of TG synthesis in hepatocytes and a decrease of TG secretion from hepatocytes.
In the setting of chronic liver injury, Ccl2, a monocytechemotactic protein induced in the injured liver, recruits monocytes and dendritic cells to the sites of inflammation [24] . In the miR-122 KO liver, Ccl2 expression increased, and inflammatory cells including monocytes producing IL-6 infiltrated. It was confirmed that miR-122 negatively regulates Ccl2 expression by binding to the 3 0 UTR of Ccl2 mRNA. Park et al. [25] demonstrated that enhanced production of the tumor-promoting cytokines IL-6 and TNF-a causes hepatic inflammation and activation of the oncogenic transcription factor STAT3. Taken together, these results suggest that over-production of Ccl2 and consequential IL-6 over-secretion from inflammatory cells contribute to hepatocarcinogenesis in miR-122 KO mice.
The initial sign of epithelial mesenchymal transition (EMT), including loss of the portal distribution of E-cadherin and gain of vimentin expression was observed in the livers of young miR-122 KO mice, followed by the loss of E-cadherin expression in the tumors of aged mice. Similarly, the expression of oncofetal genes such as a-fetoprotein (AFP), insulin-like growth factor-1 (IGF-1), and Src, as well as cancer stem cell marker genes such as Prom1, Thy1, and Epcam, were detected in the livers of young miR-122 KO mice, followed by further increases in the tumors of aged mice. The activation of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3 kinase (PI3K) signaling pathways was also detected in the livers of young miR-122 KO mice, followed by strong activation in the tumors of aged mice [19] . These data suggest that tumor-related genes are already activated early in the tumor-free livers of young miR-122 KO mice and attributed to tumor initiation and progression.
Mechanisms of antitumor function of miR-122
Recently, various target genes of miR-122 have been identified to be involved in hepatocarcinogenesis and EMT. Of these, miR-122 directly down-regulates cyclin G1 expression, and an inverse correlation between miR-122 and cyclin G1 expression exists in HCC tissues [26] . Since cyclin G1 negatively regulates p53 protein stability by acting on the B' subunit of phosphatase 2A, miR-122 increases the expression of p53 and its transcriptional activities [27] .
A disintegrin and metalloprotease 10 (ADAM10), serum response factor (SRF), and insulin-like growth factor-1 receptor (IGF-1R), which promote tumorigenesis, are validated as targets of miR-122 and are repressed by miR-122. ADAM10, SRF, and IGF-1R are up-regulated in HCC tissue compared with the adjacent normal tissue [12] . Zeng et al. suggest the following regulatory circuitry: miR-122 suppresses IGF-1R expression and attenuates IGF-1R/Akt signaling, which sustains glycogen synthase kinase-3 beta (GSK-3b) activity and in turn represses cyclin D1 expression and cell proliferation. The activated GSK-3b maintains high levels of miR-122 through activating CCAAT/enhancer-binding protein (C/EBP)a, a transcription factor of the miR-122 gene, which enforces IGF-1R suppression. Disruption of this regulatory circuitry may result in uncontrolled cell proliferation and hepatocarcinogenesis [13] . ADAM17 is another target of miR-122 and is involved in HCC metastasis. Silencing of ADAM17 resulted in a dramatic reduction of in vitro migration, invasion, in vivo tumorigenesis, and angiogenesis, which is similar to that which occurs with the restoration of miR-122 [11] .
CUTL1, a transcriptional repressor of genes specifying differentiation during development, is a target of miR-122. The amount of CUTL1 protein gradually disappeared during the progression of liver development, which was inversely correlated with the expression of miR-122 [28] . Zinc finger and BTB domain-containing 20 (ZBTB20) is a repressor of AFP gene transcription in normal liver. ZBTB20 directly binds to a region of the AFP promoter and represses its activity [29] . Recently, it was shown that miR-122 indirectly modulates the expression of ZBTB20 and regulates AFP expression [30] . The miR122-silenced HCC cells exhibit a more invasive phenotype and produce more abundant AFP. In these cells, the expression of Cutlike homeobox 1 (CUX1), which is a target of miR-122 and regulates multiple processes including cell-cycle progression, is up-regulated. CUX1 is a positive regulator of miR-214. Since ZBTB20 is a target of miR-214, the elevated expression of miR214 represses ZBTB20 translation, followed by increased expression of AFP [30] . The embryonic isoform of pyruvate kinase (Pkm2) is a target of miR-122 and is highly expressed in human embryonic stem cells (hESCs) and HCC cells. During the differentiation process of hESCs into mature hepatocytes, a reciprocal expression pattern is observed between miR-122 and Pkm2. Depleting hESCs and HCC cells of Pkm2, or overexpressing miR-122, leads to a common deficiency in self-renewal and proliferation [31] .
Various signaling pathways are deregulated in HCC. The Wnt/b-catenin pathway is activated in approximately 30 % of HCCs [32] . Wnt1 is a direct target of miR-122. miR-122 suppresses the expression of Wnt1 protein and subsequently leads to down-regulation of b-catenin and TCF-4, resulting in the attenuation of the Wnt/b-catenin signaling pathway [33] . Pituitary tumor-transforming gene 1 (PTTG1) binding factor (PBF) is a target of miR-122 [34] Overexpression of PBF is observed in 68 % of HCC (13 of 19) . PBF increases HCC cell proliferation and invasive ability and promotes tumor growth in nude mice. PBF interacts with PTTG1 and promotes its transcriptional activities by facilitating PTTG1 nuclear translocation, which in turn stimulates the transcription of tumor-promoting genes such as VEGF, FGF-2, c-myc, and MMP-2 [34] .
Regulation of miR-122 gene expression
The expression of miR-122 is correlated with liver-enriched transcription factors (LETFs), such as hepatocyte nuclear factor (HNF)1a, HNF3b, HNF4a, HNF6, and C/EBPa [10, 13, 28, 35, 36] . These LETFs are coordinately involved in the transcriptional regulation of miR-122 by binding to the miR-122 promoter as transcriptional activators. Hepatocyte differentiation is directed by a positive feedback loop that includes C/EBPa, HNF6, and miR-122 [13, 36] . As described above, miR-122 indirectly activates C/EBPa through IGF-1R suppression and resultant GSK3b activation [13] . MiR-122 stimulates HNF6 expression, although the mechanism is unclear [36] .
The expression of miR-122 is suppressed in HCC cells, which is, at least in part, explained by epigenetic modulation of miR-122. The promoter region of miR-122 is hypermethylated in HCC cells, but not in human primary hepatocytes [31] . The treatment of HCC cells with a demethylating agent, 5-Aza-2 0 deoxycytidine (5-Aza-Cd), significantly increases the gene expression of miR-122 [37] . Moreover, in HCC cells, a H3K9 histone methyl transferase down-regulates the gene expression of miR-122 by inhibiting PPARc/RXRa-mediated promoter activity, which is cancelled by cotreatment with 5-Aza-Cd and histone deacetylase inhibitor [37] .
c-myc can repress miR-122 gene expression by associating with miR-122 promoter and by down-regulating HNF3b expression, whereas miR-122 indirectly inhibits c-myc transcription by targeting the transcriptional activator E2f1 and coactivator Tfdp2 [38] . Figure 1 shows the regulators of miR-122 expression and the downstream target molecules relevant to antitumor activity of miR-122.
Therapeutic application of miR-122 against HCC
Since miR-122 is a liver-specific tumor suppressor microRNA, increasing miR-122 levels in HCC with or without antitumor agents may be a promising strategy for HCC treatment. In fact, gene transfer of miR-122 into cultured HCC cells induces apoptosis and cell-cycle arrest [39] [40] [41] . Hydrodynamic injection of miR-122 into 3-month-old miR-122 KO mice effectively impaired hepatocarcinogenesis and tumor progression, as reflected by a reduction in tumor occurrence and size [19] . Intratumor injection of miR-122 encapsulated in cationic lipid nanoparticles suppressed the growth of HCC xenograft by 50 %, which was correlated with repression of target genes and impairment of angiogenesis [42] . In addition, miR-122 sensitizes HCC cells to antitumor agents including doxorubicin [27, 43, 44] , vincristine [43] , cisplatin [44] , and sorafenib [12] by modulating the expression of multidrug resistance genes [43] and the unfolded protein response [44] .
